Novo Nordisk (NVO) Earning Somewhat Positive Media Coverage, Analysis Shows

Media coverage about Novo Nordisk (NYSE:NVO) has trended somewhat positive recently, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novo Nordisk earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.7645704642315 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

NVO has been the subject of several research analyst reports. Zacks Investment Research downgraded Novo Nordisk from a “hold” rating to a “sell” rating in a research report on Tuesday, March 27th. Deutsche Bank reiterated a “buy” rating on shares of Novo Nordisk in a research report on Monday, January 8th. Finally, JPMorgan Chase upgraded Novo Nordisk from an “underweight” rating to a “neutral” rating in a research report on Friday, December 29th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $64.00.

How to Become a New Pot Stock Millionaire

NVO traded down $0.25 during trading on Friday, hitting $48.57. The company’s stock had a trading volume of 909,946 shares, compared to its average volume of 1,479,658. Novo Nordisk has a 12 month low of $35.10 and a 12 month high of $58.37. The company has a market cap of $119,366.34, a price-to-earnings ratio of 20.76, a PEG ratio of 2.39 and a beta of 0.67.

Novo Nordisk (NYSE:NVO) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.53 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.57 by ($0.04). Novo Nordisk had a net margin of 34.09% and a return on equity of 82.72%. The business had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.27 billion. sell-side analysts forecast that Novo Nordisk will post 2.63 EPS for the current fiscal year.

Novo Nordisk declared that its Board of Directors has initiated a stock buyback plan on Thursday, February 1st that allows the company to repurchase shares. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

The firm also recently disclosed a special dividend, which was paid on Tuesday, April 3rd. Shareholders of record on Monday, March 26th were given a $0.8117 dividend. The ex-dividend date was Friday, March 23rd. This represents a yield of 0.96%. Novo Nordisk’s payout ratio is 38.89%.

ILLEGAL ACTIVITY WARNING: “Novo Nordisk (NVO) Earning Somewhat Positive Media Coverage, Analysis Shows” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3336271/novo-nordisk-nvo-earning-somewhat-positive-media-coverage-analysis-shows.html.

About Novo Nordisk

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Insider Buying and Selling by Quarter for Novo Nordisk (NYSE:NVO)

Receive News & Ratings for Novo Nordisk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Head to Head Review: On Assignment  & Its Competitors
Head to Head Review: On Assignment & Its Competitors
Contrasting Mountain Province Diamonds  and Its Rivals
Contrasting Mountain Province Diamonds and Its Rivals
Matador Resources  versus Callitas Health  Head-To-Head Comparison
Matador Resources versus Callitas Health Head-To-Head Comparison
Cousins Properties  Earns Market Perform Rating from Analysts at Wells Fargo
Cousins Properties Earns Market Perform Rating from Analysts at Wells Fargo
$63.31 Million in Sales Expected for First Bancorp  This Quarter
$63.31 Million in Sales Expected for First Bancorp This Quarter
Royal Bank of Canada Reaffirms “Hold” Rating for BancorpSouth Bank
Royal Bank of Canada Reaffirms “Hold” Rating for BancorpSouth Bank


© 2006-2018 Ticker Report. Google+.